Healthcare / BiotechnologySão Paulo
$6.87
-0.26 (-3.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-111.7M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$940M
P/E
57.3x
↑EV/EBITDA
76.8x
↑ROE
-2.1%
↓Gross Margin
31.6%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+36.9%
FCF CAGR
—
FCF margin
-49.5%
FCF / Net income
19.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $269.3M · net income $-6.7M · FCF $-133.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $269.3M | $269.3M | $142.9M | $118.2M | $105.0M |
| Net Income | $-6.7M | $-6.7M | $-77.2M | $-81.1M | $-92.6M |
| EBITDA | $12.6M | $12.6M | $-53.1M | $-56.2M | $-66.7M |
| EPS | -0.05 | -0.05 | -0.61 | -0.95 | -1.22 |
| Gross Margin | 31.6% | 31.6% | 12.5% | 19.7% | 15.2% |
| Operating Margin | -1.8% | -1.8% | -56.5% | -61.0% | -82.2% |
| Net Margin | -2.5% | -2.5% | -54.0% | -68.7% | -88.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.46 | 1.25 | 1.08 |
| Current Ratio | 1.77 | 1.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-133.2M | $-133.2M | $-111.7M | $-81.0M | $-68.4M |
| Returns | |||||
| ROE | -2.1% | -2.1% | -29.4% | -66.0% | -58.2% |
| Valuation | |||||
| P/E | 57.25 | 57.25 | — | — | — |
| EV/EBITDA | 76.79 | 76.79 | — | — | — |
| P/B | 2.85 | 2.85 | 5.04 | 4.08 | 2.95 |
| Growth & Yield | |||||
| Revenue Growth | 88.4% | 88.4% | 20.9% | 12.6% | — |
| EPS Growth | 91.8% | 91.8% | 35.7% | 22.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.61 → -0.05
Residual
-34.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.